Any feedback?
Literature summary for 3.4.14.5 extracted from
- Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes (2007), Curr. Top. Med. Chem., 7, 547-555.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | pre-clinical and clinical studies on DPP-IV inhibitors demonstrate significant potential for their application as therapeutic agents in the managment of type 2 diabetes | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| NVP DPP 728 | - |
Homo sapiens |  |
| P32/98 | - |
Homo sapiens | |
| PSN9301 | - |
Homo sapiens | |
| saxagliptin | - |
Homo sapiens | |
| sitagliptin | - |
Homo sapiens | |
| SYR322 | - |
Homo sapiens | |
| vildagliptin | - |
Homo sapiens | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| dipeptidyl peptidase IV | - |
Homo sapiens |
| DPP-IV | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
